NEW YORK--Pfizer Inc. (NYSE: PFE) today announced that its subsidiary,
Zoetis™ Inc. (zō-EH-tis), filed a registration statement with the U.S.
Securities and Exchange Commission for a potential initial public
offering (IPO) of Class A common stock. The offering is expected to
represent an ownership stake of up to 20 percent. Prior to completion of
the offering, which is targeted for the first half of 2013, Pfizer will
transfer its animal health business to Zoetis. The number of shares to
be offered and the price range for the offering have not yet been
determined.
A registration statement relating to these securities has been filed
with the Securities and Exchange Commission but has not yet become
effective. These securities may not be sold nor may offers to buy be
accepted prior to the time the registration statement becomes effective.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
J.P. Morgan, BofA Merrill Lynch and Morgan Stanley will act as the joint
book-running managers for the proposed IPO. When available, copies of
the preliminary prospectus relating to the proposed IPO may be obtained
from J.P. Morgan, Attention: Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717, or telephone: 1-866-803-9204; BofA
Merrill Lynch, 222 Broadway, 7th Floor, New York, NY 10038, Attn:
Prospectus Department, or email: dg.prospectus_requests@baml.com;
or Morgan Stanley, Attention: Prospectus Department, 180 Varick Street,
2nd Floor, New York, NY 10014, or telephone: 1-866-718-1649, or email: prospectus@morganstanley.com.
About Pfizer Inc.: Working together for a healthier world®
At Pfizer, we apply science and our global resources to improve health
and well-being at every stage of life. We strive to set the standard for
quality, safety and value in the discovery, development and
manufacturing of medicines for people and animals. Our diversified
global health care portfolio includes human and animal biologic and
small molecule medicines and vaccines, as well as nutritional products
and many of the world’s best-known consumer products. Every day, Pfizer
colleagues work across developed and emerging markets to advance
wellness, prevention, treatments and cures that challenge the most
feared diseases of our time. Consistent with our responsibility as the
world’s leading biopharmaceutical company, we also collaborate with
health care providers, governments and local communities to support and
expand access to reliable, affordable health care around the world. For
more than 150 years, Pfizer has worked to make a difference for all who
rely on us.
About Pfizer Animal Health
Pfizer Animal Health, a business unit of Pfizer Inc., is a global leader
in the discovery, development, manufacture and commercialization of
animal health medicines and vaccines, with a focus on both livestock and
companion animals. For more than 60 years, we have been committed to
enhancing the health of animals and bringing solutions to our customers
who raise and care for them.
DISCLOSURE NOTICE: The information contained in this release is as of
August 13, 2012. Pfizer assumes no obligation to update forward-looking
statements contained in this release as the result of new information or
future events or developments.
This release contains forward-looking information that involves
substantial risks and uncertainties about a potential initial public
offering of a minority ownership stake in Pfizer’s Animal Health
business. Such risks and uncertainties include, among other things, the
possibility that the initial public offering will not be consummated
within the anticipated time period or at all, including as the result of
regulatory, market or other factors; risks relating to Pfizer Animal
Health as a standalone business as the result of the variables and
uncertainties inherent in business, financial and operating performance,
including, among other things, competitive developments and general
economic, political, business, industry, regulatory and market
conditions; and the potential for disruption to Pfizer’s Animal Health
business as the result of the initial public offering.
A further description of risks and uncertainties can be found in
Pfizer’s Annual Report on Form 10-K for the fiscal year ended December
31, 2011 and in its reports on Form 10-Q and Form 8-K.
All content set forth in this communication is subject to
consultation with works councils, unions and employee representatives as
required by and subject to local laws and regulations.
Pfizer Inc.
Media Contact:
Joan Campion, 212-733-2798
joan.campion@pfizer.com
or
Investor Contact:
Chuck Triano, 212-733-3901
charles.e.triano@pfizer.com